Kolexia
Vienot Angelique Gastro-entérologie
Vienot Angelique
Gastro-entérologie
Le Mittan Annexe Du Hnfc
Montbéliard, France
105 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Adénocarcinome Tumeurs du pancréas Tumeurs des voies biliaires Tumeurs colorectales Carcinome épidermoïde Tumeurs du foie Cholangiocarcinome Carcinome hépatocellulaire

Collaborateurs

Voir plus
Borg Christophe
Borg Christophe
Hôpital Nord Franche-Comté, Montbéliard, France
Jary Marine
Jary Marine
Hôpital Estaing, Clermont-Ferrand, France
Klajer Elodie
Klajer Elodie
Hôpital Jean-Minjoz, Besançon, France
Neuzillet Cindy
Neuzillet Cindy
Institut Curie, Saint-Cloud, France

Industries

Voir plus
Servier
3 collaboration(s)
Dernière en 2023
Ipsen
2 collaboration(s)
Dernière en 2022
MSD
2 collaboration(s)
Dernière en 2023
Bayer
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
ASPIRE: A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Essai Clinique (Panbela Therapeutics, Inc.)   12 mars 2024
ALIX: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)
Essai Clinique (CHU Besançon)   06 février 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   17 janvier 2024
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study: Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   03 janvier 2024
SPARTANA: Spartalizumab, mDCF (Docetaxel, Cisplatin and 5-fluorouracil) and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma. A Phase IIA Study
Essai Clinique (CHU Besançon)   21 décembre 2023
CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Oncoimmunology   21 décembre 2023
REPROGRAM-02: Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study
Essai Clinique (CHU Besançon)   21 décembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
GEMPAX: A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma
Essai Clinique (Unicancer)   07 novembre 2023
1642P Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023